-
Je něco špatně v tomto záznamu ?
Provizórikus veserákaltípusok a 2016. évi WHO-klasszifikációt követően [Provisional renal cell carcinoma subsets following the 2016 WHO classification]
A. Jenei, O. Hes, L. Kuthi,
Jazyk maďarština Země Maďarsko
Typ dokumentu časopisecké články, přehledy
PubMed
31928058
DOI
10.1556/650.2020.31654
Knihovny.cz E-zdroje
- MeSH
- karcinom z renálních buněk * MeSH
- ledviny MeSH
- lidé MeSH
- nádorové biomarkery MeSH
- nádory ledvin * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Maďarsko MeSH
Renal cell carcinoma (RCC) represents a heterogenous group of malignant tumors that originate from the kidney parenchyma. The different entities have their own specific epidemiological, morphological, immunohistochemical, genetic and clinical characteristics. The new WHO classification of renal tumors was published in 2016, and it takes all of these features together into account. Although in the past three years, several emerging subtypes have been described, these are not yet included in the current classification. In this review paper, these entities are summarized in details including the following emerging subsets: thyroid-like follicular carcinoma, ALK rearrangement-associated RCC, renal cell carcinoma with prominent smooth muscle stroma, fumarate hydratase-deficient RCC, biphasic squamoid papillary RCC, eosinophilic solid and cystic RCC, atrophic kidney-like RCC, clear cell RCC with giant cells and emperipolesis, Warthin-like papillary RCC, low-grade oncocytic renal tumor (CD117-negative; CK7-positive), high-grade oncocytic renal tumor, TCEB1-mutated RCC and chromophobe RCC with neuroendocrine features. These entities are mostly diagnosed as RCC unclassified. The aim of this study is to introduce these subsets to the Hungarian pathologists, oncologists and urologists, to prompt diagnostic accuracy and to facilitate a collection along with a consecutive analysis of these cases. Orv Hetil. 2020; 161(3): 83-94.
Charles University Hospital Plzeň
Patológiai Intézet Szegedi Tudományegyetem Általános Orvostudományi Kar Szeged Állomás u 1 6725
Provisional renal cell carcinoma subsets following the 2016 WHO classification
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005580
- 003
- CZ-PrNML
- 005
- 20200526132538.0
- 007
- ta
- 008
- 200511s2020 hu f 000 0|hun||
- 009
- AR
- 024 7_
- $a 10.1556/650.2020.31654 $2 doi
- 035 __
- $a (PubMed)31928058
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a hun
- 044 __
- $a hu
- 100 1_
- $a Jenei, Alex $u Patológiai Intézet, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Állomás u 1., 6725.
- 245 10
- $a Provizórikus veserákaltípusok a 2016. évi WHO-klasszifikációt követően / $c A. Jenei, O. Hes, L. Kuthi,
- 246 31
- $a [Provisional renal cell carcinoma subsets following the 2016 WHO classification].
- 520 9_
- $a Renal cell carcinoma (RCC) represents a heterogenous group of malignant tumors that originate from the kidney parenchyma. The different entities have their own specific epidemiological, morphological, immunohistochemical, genetic and clinical characteristics. The new WHO classification of renal tumors was published in 2016, and it takes all of these features together into account. Although in the past three years, several emerging subtypes have been described, these are not yet included in the current classification. In this review paper, these entities are summarized in details including the following emerging subsets: thyroid-like follicular carcinoma, ALK rearrangement-associated RCC, renal cell carcinoma with prominent smooth muscle stroma, fumarate hydratase-deficient RCC, biphasic squamoid papillary RCC, eosinophilic solid and cystic RCC, atrophic kidney-like RCC, clear cell RCC with giant cells and emperipolesis, Warthin-like papillary RCC, low-grade oncocytic renal tumor (CD117-negative; CK7-positive), high-grade oncocytic renal tumor, TCEB1-mutated RCC and chromophobe RCC with neuroendocrine features. These entities are mostly diagnosed as RCC unclassified. The aim of this study is to introduce these subsets to the Hungarian pathologists, oncologists and urologists, to prompt diagnostic accuracy and to facilitate a collection along with a consecutive analysis of these cases. Orv Hetil. 2020; 161(3): 83-94.
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 12
- $a karcinom z renálních buněk $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $7 D007668
- 650 12
- $a nádory ledvin $7 D007680
- 651 _2
- $a Maďarsko $7 D006814
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hes, Ondrej $u Charles University Hospital Plzeň.
- 700 1_
- $a Kuthi, Levente $u Patológiai Intézet, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Állomás u 1., 6725.
- 773 0_
- $w MED00003650 $t Orvosi hetilap $x 1788-6120 $g Roč. 161, č. 3 (2020), s. 83-94
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31928058 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526132535 $b ABA008
- 999 __
- $a ok $b bmc $g 1524438 $s 1095636
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 161 $c 3 $d 83-94 $e - $i 1788-6120 $m Orvosi hetilap $n Orv Hetil $x MED00003650
- LZP __
- $a Pubmed-20200511